Etienne Caron, PhD

Dr. Caron is a Canadian scientist with a background in Biotechnology and Systems Immunology. He received his PhD from the University of Montreal in Canada under the guidance of Dr. Claude Perreault and completed his education at ETH-Zürich in Switzerland under the guidance of Dr. Ruedi Aebersold. Dr. Caron is known for his international leadership and expertise in immunopeptidomics for the global analysis of MHC-associated peptides using mass spectrometry technologies. His scientific program has the potential to revolutionize the research on vaccine design, cancer immunotherapy, infectious and autoimmune diseases, including treatment of neurodegenerative diseases and aging.

Dr. Caron began his career as a Principal Investigator in 2018 at the University of Montreal, Canada. In 2023, Dr. Caron was recruited by the Yale Center for Immuno-Oncology (YCIO) and the Department of Immunobiology. He is also currently a member of the Yale Center for Infection and Immunity (CII), and the Yale Center for Systems and Engineering Immunology (CSEI).

Dr. Caron initiated the Human Immunopeptidome Project and was Chair from 2015 to 2020. He was the first to identify tumor-specific mutated peptides, known as neoantigens, using mass spectrometry and to develop data-independent acquisition mass spectrometry for the analysis of immunopeptidomes. He also initiated the SysteMHC Atlas Project as the first public data repository toward a community-driven global mapping of the human immunopeptidome.

Dr. Caron has co-founded the start-up Neomabs Biotechnologies Inc., with the goal of transforming the treatment of childhood leukemia through targeted immunotherapies. He has also provided distinctive services to the life sciences industry through numerous collaborations with companies such as Biognosys, Flagship Pioneering, and Bruker Daltonics.